Eli Lilly, Nordisk move to dismiss US antitrust claims over GLP-1 drugs
MLex Summary: Eli Lilly and Novo Nordisk told a US federal judge they didn't enter into exclusive agreements with telehealth platforms to block those platforms from selling Strive’s competing compounded GLP-1...To view the full article, register now.
Already a subscriber? Click here to view full article